The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 49 | — | 20.1x | Near average | |
Growth | 62 | — | 5.6% | Near average | |
Quality | 14 | -57.4% | 7.6% | Below average | |
Safety | 73 | 0.3x | 0.4x | Above average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
ORIC Pharmaceuticals, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy ORIC Pharmaceuticals, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
ORIC stock shows remarkable stability in analyst estimates over the past 30 days, with the average price target holding steady at 20.4 dollars despite the significant gap between the current price (8.32 dollars) and the target. The consistent consensus among 7 analysts reflects a state of anticipation for clinical trial results, especially given the absence of any expected revenue and the continued recording of losses in earnings per share (EPS) for upcoming fiscal periods.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.